Outcomes of Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis in Acute Myeloid Leukemia and Myelodysplastic Syndromes Patients Over 70 Years of Age: A Comparative Analysis by Age Group
Carefully selected adults over 70 can safely undergo transplant for blood cancers with individualized risk assessment rather than automatic age-based rejection.
This CIBMTR registry analysis of 431 patients demonstrates that allogeneic HCT with PTCy-based GVHD prophylaxis is feasible in carefully selected AML/MDS patients over age 70, with higher NRM and modestly inferior OS but comparable relapse rates and GVHD control compared to younger patients. The findings support individualized rather than categorical age-based exclusion from transplantation in elderly AML/MDS patients.
What the study was
- Study design
- Retrospective multicenter registry analysis (CIBMTR)
- Population
- AML/MDS patients >70 years undergoing allogeneic HCT with PTCy (2012-2017)
- Sample size
- 431
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Clin Lymphoma Myeloma Leuk
Why it surfaced
Elderly AML/MDS patients historically undertreated; CIBMTR multicenter registry provides strong real-world evidence; supports expanding HCT access to >70 age group with individualized selection.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.